Back to Market返回行情

INMD InMode Ltd.

USHealthcare
$15.28+1.80%ClosedMarket Cap: $878.3M

As of 2026-07-10 16:00

Why INMD matters now

InMode Ltd. (INMD) is a US stock in Healthcare. The latest InvestLog snapshot shows $15.28 with +1.80% on the session and $878.3M in market capitalization; recent performance reads 1-month -4.08% and YTD -8.78%.

The latest financial table shown here is Q1 2026, with revenue of $82.0M, net income of $11.6M, and EPS of $0.18. Investors can compare that operating picture with valuation signals such as P/E 9.14 and FCF yield 11.1%.

The latest indexable market news headline is "InMode Confirms Receipt of Unsolicited Proposal" from PRNewsWire.

Additional event context on this page matters because analyst consensus is Hold with a median target of $18.00; recent insider activity includes Moshe Itzkovich filing . These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

9.14

PEG

P/B

1.28

P/S

2.17

EV/EBITDA

4.13

DCF Value

$36.01

FCF Yield

11.1%

Div Yield

0.0%

Margins & Returns

Gross Margin

77.8%

Operating Margin

21.3%

Net Margin

23.3%

ROE

13.3%

ROA

11.6%

ROIC

10.1%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$82.0M$11.6M$0.18
Q4 2025$103.9M$27.0M$0.42
FY 2025$370.5M$93.8M$1.43
Q3 2025$93.2M$21.9M$0.34

Analyst Ratings

Consensus

Hold

Target (Consensus)

$18.00

Target (Median)

$18.00

Target Range

$17.00 - $19.00

Strong Buy: 0Buy: 0Hold: 5Sell: 0Strong Sell: 0
BairdNeutral
2026-05-07
BarclaysOverweight
2026-05-07
Canaccord GenuityHold
2025-12-17
UBSNeutral
2025-11-06
NeedhamHold
2025-10-10

Trading Activity

Insider Trades

Moshe Itzkovichofficer: Chief Financial Officer
Sell2026-05-26
Moshe Itzkovichofficer: Chief Financial Officer
Sell2026-05-26
Moshe Itzkovichofficer: Chief Financial Officer
Sell2026-05-26
Nass Shlomodirector
Sell2026-05-26
Ron Hadardirector
Sell2026-03-18

Company Info

Sector

Healthcare

Industry

Medical - Devices

Country

IL

Exchange

Beta

1.93

InMode Ltd. is a medical technology company that engineers, produces, and commercializes aesthetic medical devices globally, including within the United States. The firm's product portfolio is extensive, covering both less-invasive and non-surgical solutions. A core focus lies in their minimally invasive offerings, which leverage exclusive radiofrequency-assisted lipolysis (RFAL) and deep subdermal fractional radiofrequency technologies. These advanced devices facilitate a range of procedures, such as liposuction with concurrent skin firming, body and facial sculpting, intensive skin resurfacing treatments, and various women's health-related aesthetic interventions. Beyond these, InMode also provides non-invasive medical aesthetic products designed to address numerous cosmetic concerns. These include lasting hair removal, facial skin revitalization, the reduction of wrinkles, cellulite improvement, enhancing overall dermal quality and texture, and treating minor vascular and pigmented skin imperfections. Furthermore, the company develops automated, hands-free medical aesthetic systems for applications like dermal tightening, adipose tissue reduction, and muscular toning. Established in 2008, InMode Ltd. operates from its headquarters in Yokneam, Israel. The company was previously known as Invasix Ltd. before officially changing its name in November 2017.